Clinical benefits of evolocumab appear less than hoped – Authors' reply

File(s)

FOURIER, Lancet Reply clinical benefits of evolocumab apperas less than hoped REPLY.docx (17.7 KB)

Accepted version

Show more

Author(s)

Giugliano, Robert P

Keech, Anthony C

Sever, Peter S

Pedersen, Terje R

Sabatine, Marc S

Type

Journal Article

Date Issued

2018-03-10

Date Acceptance

2018-03-01

Citation

LANCET, 2018, 391 (10124), pp.934-935

URI

http://hdl.handle.net/10044/1/62769

DOI

https://www.dx.doi.org/10.1016/S0140-6736(18)30529-4

ISSN

0140-6736

Publisher

ELSEVIER SCIENCE INC

Start Page

934

End Page

935

Journal / Book Title

LANCET

Volume

391

Issue

10124

Copyright Statement

© 2018 Elsevier Ltd. All rights reserved. This manuscript is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/

Sponsor

National Institute for Health Research

National Institute for Health Research

Amgen Inc

Identifier

http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000427363100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202

Grant Number

NF-SI-0513-10059

NF-SI-0513-10059

20110118

Subjects

Science & Technology

Life Sciences & Biomedicine

Medicine, General & Internal

General & Internal Medicine

LDL-CHOLESTEROL

SECONDARY ANALYSIS

EFFICACY

SAFETY

TRIAL

PCSK9

RISK

Publication Status

Published

Date Publish Online

2018-03-08